Description of Research Expertise
neuroendocrine tumors and esophagogastric cancer
Selected Publications
Eads JR, Catalano PJ, Fisher GA, Rubin D, Iagaru A, Klimstra D, Konda B, Kwong MS, Chan JA, De Jesus-Acosta A, Halfdanarson TR, Shaib WL, Soares HP, Hong SC, Wong TZ, O'Dwyer PJ: Randomized phase II study of platinum and etoposide versus temozolomide and capecitabine in patients with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms: ECOG-ACRIN EA2142. American Society of Clinical Oncology Annual Meeting, Chicago, IL : 2022.
Lau-Min KS, Li Y, Eads JR, Mamtani R, Getz KD: Association between timely targeted treatment and outcomes in patients with metastatic Her2-overexpressing gastroesophageal adenocarcinoma Cancer 128 (9): 1853-1862,2022.
Eads JR: Is it time yet for adjuvant immunotherapy for patients with DNA mismatch repair deficient gastric cancer? Ann Surg Oncol 29 (4): 2141-2143,2022.
Chapin WJ, Massa RC, Eads JR: Evolving standards of care for neoadjuvant and adjuvant therapy in esophageal, gastroesophageal junction, and gastric cancer Clin Adv in Hem and Oncol 19 (12): 784-793,2021.
Eads JR: Cardiovascular concerns in the management of esophageal cancer patients JACC Cardio Oncol
3 (5): 722-724,2021.
Eads JR, Haller DG: Primary chemoradiotherapy for older patients with esophageal cancer JAMA Oncology 7 (10): 1451-1452,2021.
Lee H, Nakamoto R, Moore SE, Pantel AR, Eads JR, Aparici CM, Pryma DA: Combined quantification of 18F-FDG and 68Ga-DOTATATE PET/CT for prognosis in high-grade gastroenteropancreatic neuroendocrine neoplasms Acad Radiol 29 (9): 1453.,2021.
Lau-Min KS, Li Y, Eads JR, Mamtani R, Getz KD: Adherence to and determinants of guideline-recommended biomarker testing and targeted therapy in patients with gastroesophageal adenocarcinoma: Insights from routine practice Cancer 127 (14): 2562-2570,2021.
Lau-Min KS, Li Y, Eads JR, Wang X, Meropol NJ, Mamtani R, Getz KD: Adherence to and determinants of guideline-recommended biomarker testing and targeted therapy in gastroesophageal adenocarcinoma: insights from routine practice Cancer 127 (14): 2562-2570,2021.
Eads JR, Graham N, Catalano PJ, Gibson MK, Rajdev L, Khullar O, Lin SH, Gatsonis C, Wistuba II, Sanjeevaiah A, Benson AB, Bahary N, Spencer KR, Saba NF, Hamilton SR, Staley CA, Chakravarthy B, Fisher GA, Wong TZ, O'Dwyer PJ: A phase II/III study of perioperative nivolumab and ipilimumab in patients with locoregional esophageal and gastroesophageal junction adenocarcinoma: results of a safety run in-a trial of the ECOG-ACRIN cancer research group (EA2174) American Society of Clinical Oncology Annual Meeting, Chicago, IL : 2021.
Academic Contact Information
Perelman Center for Advanced Medicine
10th Floor South Pavilion
Philadelphia,
PA
19104
Patient appointments: 800-789-7366